CVRX Stock Gains on Unveiling of Barostim's Positive Study Data

Zacks09-16

CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2468184783?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7","is_english":true,"pubTime":"2024-09-16 22:37","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2468184783","market":"us","top_or_hot":-1,"title":"CVRX Stock Gains on Unveiling of Barostim's Positive Study Data","media":"Zacks","content":"<div>\n<p>CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvrx-stock-gains-unveiling-barostims-143700833.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CVRX Stock Gains on Unveiling of Barostim's Positive Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCVRX Stock Gains on Unveiling of Barostim's Positive Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-16 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cvrx-stock-gains-unveiling-barostims-143700833.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cvrx-stock-gains-unveiling-barostims-143700833.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1854104046.USD","symbol_name":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/cvrx-stock-gains-unveiling-barostims-143700833.html","article_id":"2468184783","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0y7pHAbd2ah0Qunql6MeVQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b35c1538fbd501bfb8e20b349661fde7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2468184783","pubTimestamp":1726497420,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: Heart Failure.The publication builds on the data from the BeAT-HF trial published in 2024 in the European Journal of Heart Failure, demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction.Shares of CVRX gained 3.2% on Friday on the announcement of the publication of the new data.Barostim technology stimulates baroreceptors located in the carotid artery wall with electrical pulses. The body's baroreflex is triggered by the pulses, which cause the heart to respond. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the United States. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.Some better-ranked st","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4082":"医疗保健设备","BK4120":"环境与设施服务","DGX":"奎斯特诊疗","ABM":"反导工业公司","BK4196":"保健护理服务","BK4588":"碎股","BK4583":"猴痘概念","CVRX":"CVRx, Inc.","BK4567":"ESG概念","UHS":"Universal Health Services Inc Cl","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","BK4185":"保健护理机构","BK4585":"ETF&股票定投概念","BK4539":"次新股"},"translate_title":"Barostim积极研究数据公布后CVRX股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABM":1,"CVRX":1,"DGX":1,"UHS":1},"content_text":"CVRx CVRX recently announced the publication of new data supporting its Barostim technology for treating heart failure. The data was published in the Journal of the American College of Cardiology: Heart Failure.\nThe publication builds on the data from the BeAT-HF trial published in 2024 in the European Journal of Heart Failure, demonstrating the long-term sustained symptomatic benefits of Barostim in heart failure patients with reduced ejection fraction.\nShares of CVRX gained 3.2% on Friday on the announcement of the publication of the new data.\nMore on CVRX’s New Study Data\nBarostim technology stimulates baroreceptors located in the carotid artery wall with electrical pulses. The body's baroreflex is triggered by the pulses, which cause the heart to respond. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the United States. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area.\nBarostim was used in conjunction with guideline-directed medical therapy (GDMT) by the study participants. Comparing GDMT alone with a range of physical and psychological indicators, the participants reported feeling noticeably better. The capacity to work around the house, sleep and exercise all significantly improved as a result. Recipients reported feeling less depressed after taking Barostim. Physical measures included reduced breathing difficulties, discomfort and exhaustion and improved mobility and capacity to carry out daily tasks.\nThe published data showcased the durable improvements up to 24 months in the individual components of the Minnesota Living with Heart Failure and EuroQual-5D quality of life measures. The CVRx management believes that this analysis of the long-term BeAT-HF data will support the shared decision-making of patients and physicians when considering Barostim therapy.\nFavorable Industry Prospects for CRVX\nPer a report by Coherent Market Insights, the global cardiac implant market size was estimated to be $37.8 billion in 2022 and is projected to witness a CAGR of 8.1% during the 2022-2030 period.\nGiven the market potential, CVRX’s Barostim technologies’ positive study is likely to increase its demand and provide a boost to the company’s business.\nPrice Performance of CVRX Stock\nIn the past six months, CVRX’s shares have plunged 62% against the industry’s 2.1% growth. The S&P 500 has increased 9.2% in the same time frame.\nImage Source: Zacks Investment Research\nCVRX’s Zacks Rank & Stocks to Consider\nCVRX carries a Zacks Rank #3 (Hold) at present.\nSome better-ranked stocks in the broader medical space are Universal Health Service UHS, Quest Diagnostics DGX and ABM Industries ABM. While Universal Health Service currently sports a Zacks Rank #1 (Strong Buy), Quest Diagnostics and ABM Industries carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nUniversal Health Service has an estimated long-term growth rate of 19%. UHS’ earnings surpassed estimates in each of the trailing four quarters, the average surprise being 14.58%.\nThe company has gained 41.1% compared with the industry's 34.8% growth so far this year.\nQuest Diagnostics has an estimated long-term growth rate of 6.20%. DGX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%.\nThe company’s shares have gained 3.7% so far this year compared with the industry’s 10.2% growth.\nABM Industries’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 7.34%.\nABM's shares have risen 24.1% so far this year compared with the industry’s 11.9% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nQuest Diagnostics Incorporated (DGX) : Free Stock Analysis Report\nUniversal Health Services, Inc. (UHS) : Free Stock Analysis Report\nABM Industries Incorporated (ABM) : Free Stock Analysis Report\nCVRx, Inc. (CVRX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2468184783"}